What we do Medico Intercontinental Ltd trades pharmaceutical products and supports bio-pharmaceutical companies in delivering innovative therapies globally, focusing on improving patient health. |
Founded in 1,984 |
Market share Recognized player in pharmaceutical trading with growing market presence and strategic investments in biotech subsidiaries. |
Problem solved Bridges innovative bio-pharma products to global markets, enhancing access to novel treatments for rare diseases. |
Top clients or who we serve B2B focus serving pharmaceutical companies and research-based biopharma enterprises globally. |
Key management Mr. Samir Shah (Managing Director), Mr. Dilipkumar Bhogilal Shah (CEO), Mr. Jay Sharadkumar Shah (CFO) |
Our journey and innovations Incorporated in 1984, renamed in 2018; expanded through joint ventures and subsidiaries, investing in unique products like Vitamin D3 portfolios. |
Where we operate India headquarters with subsidiaries and joint ventures expanding footprint in pharmaceutical and allied sectors. |
Top products or what we offer Pharmaceutical trading, novel therapies platform for bio-pharma companies; key offerings include Vitamin D3 products via subsidiaries. |
Top brands Medico Lab (joint venture); subsidiaries include Ritz Formulations, Sungrace Pharma, Azillian Healthcare, Evagrace Pharma. |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue from trading operations with recurring partnerships and strategic investments supporting growth. |
Our industry position Strong segment presence in pharmaceutical trading with robust consolidated financial growth and diversified subsidiaries. |
Financial highlights FY 2024-25 consolidated revenue Rs. 96.02 Cr with net profit Rs. 5.06 Cr; consistent revenue and profit growth year over year. |
Geographical revenue split - |
Order book - |
Whats driving growth Growing pharmaceutical demand, strategic acquisitions, joint ventures, and expansion of novel therapeutic portfolios. |
Our future plans Investing in subsidiaries, expanding joint ventures, increasing capital base, and scaling biotech product offerings globally. |
Our green promise - |
Our people and values Committed leadership with a culture emphasizing innovation, patient-centric approach, and ethical governance. |
Key challenges ahead Competition in pharma trading, regulatory compliance, and managing expansion risks in new business ventures. |
Interesting facts Strategic shift from leasing finance to pharma trading with active investments in unique biopharma portfolios since 2018. |
Risks and strategy Mitigates business and regulatory risks through diversified subsidiaries, strong internal controls, and risk management frameworks. |
